MX2009010683A - Conjugado de wortmanina-rapamicina y usos del mismo. - Google Patents

Conjugado de wortmanina-rapamicina y usos del mismo.

Info

Publication number
MX2009010683A
MX2009010683A MX2009010683A MX2009010683A MX2009010683A MX 2009010683 A MX2009010683 A MX 2009010683A MX 2009010683 A MX2009010683 A MX 2009010683A MX 2009010683 A MX2009010683 A MX 2009010683A MX 2009010683 A MX2009010683 A MX 2009010683A
Authority
MX
Mexico
Prior art keywords
conjugate
wortmanina
rapamicina
same
wortmanin
Prior art date
Application number
MX2009010683A
Other languages
English (en)
Inventor
Arie Zask
Jianxin Gu
Mark Ruppen
Ker Yu
Judy Lucas
Semiramis Ayral-Kaloustian
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009010683A publication Critical patent/MX2009010683A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe un conjugado de rapamicina - wortmanina en el cual el conjugado se forma al enlazar la rapamicina y wortmanina juntas de tal manera que la rapamicina y la wortmanina se separan después de administrarse a un sujeto; se describe el uso de un conjugado en un régimen antineoplásico.
MX2009010683A 2007-04-05 2008-04-03 Conjugado de wortmanina-rapamicina y usos del mismo. MX2009010683A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92190707P 2007-04-05 2007-04-05
PCT/US2008/004331 WO2008124026A1 (en) 2007-04-05 2008-04-03 Wortmannin-rapamycin conjugate and uses thereof

Publications (1)

Publication Number Publication Date
MX2009010683A true MX2009010683A (es) 2010-01-20

Family

ID=39627784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010683A MX2009010683A (es) 2007-04-05 2008-04-03 Conjugado de wortmanina-rapamicina y usos del mismo.

Country Status (6)

Country Link
US (1) US20080249123A1 (es)
EP (1) EP2132212A1 (es)
JP (1) JP2010523566A (es)
CA (1) CA2678415A1 (es)
MX (1) MX2009010683A (es)
WO (1) WO2008124026A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2015161139A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9295673B2 (en) * 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
WO2014059295A1 (en) 2012-10-12 2014-04-17 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
EP2968340A4 (en) * 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
JP2018528257A (ja) * 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
US20210154372A1 (en) 2017-05-15 2021-05-27 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
MX2020011565A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
EP3880266B1 (en) 2018-11-14 2025-05-07 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
EP3952937A1 (en) 2019-04-08 2022-02-16 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
CA3256390A1 (en) 2022-05-25 2023-11-30 Revolution Medicines, Inc. CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG47580A1 (en) * 1992-10-13 1998-04-17 American Home Prod Carbamates of rapamycin
ES2295093T3 (es) * 1993-04-23 2008-04-16 Wyeth Conjugados y anticuerpos de rapamicina.
CA2287387C (en) * 1997-05-14 2010-02-16 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
MXPA05011248A (es) * 2003-04-23 2005-12-14 Wyeth Corp Derivados de wortmanina solubles en agua.
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
EP1940386A4 (en) * 2005-09-01 2010-06-23 Beth Israel Hospital WORDMAN'S CONJUGATES AND USES THEREOF
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof

Also Published As

Publication number Publication date
EP2132212A1 (en) 2009-12-16
WO2008124026A1 (en) 2008-10-16
US20080249123A1 (en) 2008-10-09
CA2678415A1 (en) 2008-10-16
JP2010523566A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
MX2009010683A (es) Conjugado de wortmanina-rapamicina y usos del mismo.
CO6341574A2 (es) Composiciones de antagonistas dl pd-1 y metodos de uso
PA8842201A1 (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
CO6491052A2 (es) Compuestos espirociclicos que contienen notrogeno y su uso medicinal
GT201500105A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
DOP2014000200A (es) Compuestos inhibidores de raf
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CR20110558A (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS Y MÉTODOS DE USO
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
PE20161034A1 (es) Composiciones y metodos para reducir eventos adversos cardiovasculares graves
CL2011001712A1 (es) Combinacion de 0,1 a 1 mg de al menos un estimulador de sgc seleccionado de un grupo definido con 2,5 a 20 mg de un inhibidor de pde5 seleccionado de otro grupo; formulacion farmaceutica que la comprende y uso en el tratamiento de la disfuncion sexual masculina.
UA109037C2 (uk) Триазолопіридини
MX2011011596A (es) Perifosina y capecitabina como un tratamiento combinado para cancer.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MX2020002814A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
CL2014000606A1 (es) Combinacion farmaceutica que comprende al compuesto 2-{2-[(2s)-2-metil-2,3-dihidro-1h-indol-1-il]-2-oxoetil}-6-(morfolin-4-il)pirimidin-4-(3h)-ona y al menos un inhibidor de la via de mapk; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento del cancer.
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
PE20170469A1 (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
ECSP10010661A (es) Dronedarona para la prevención de la cardioversión
CL2011002719A1 (es) Composición nutricional que comprende un extracto de manzana y que reduce los síntomas de la alergia a los alimentos, en especial, en niños.